Session » Immunological Complications of Therapy Poster

Date: Monday, November 9, 2020

Time: 9:00AM-11:00AM

Meeting: ACR Convergence 2020

9:00AM-11:00AM: Abstract Number: 1576

Acute Respiratory Viral Adverse Events During Use of Antirheumatic Disease Therapies: A Scoping Review

9:00AM-11:00AM: Abstract Number: 1579

Assessing the Effect of Calcineurin Inhibitors for Immune-related Adverse Event Management on Tumor Response

9:00AM-11:00AM: Abstract Number: 1567

Association of Blood Count Biomarkers and Clinical Features with Immune Related Adverse Events (irAEs) in Patients with Cancer Treated with Checkpoint Inhibitors (CPI)

9:00AM-11:00AM: Abstract Number: 1575

CD6 Is a Target for Cancer Immunotherapy

9:00AM-11:00AM: Abstract Number: 1572

Clinical Characteristics of Methotrexate Associated Lymphoproliferative Disorders and RA Treatment After Lymphoproliferative Onset in 92 Cases

9:00AM-11:00AM: Abstract Number: 1571

Distinct T Cell Responses in Inflammatory Arthritis Associated with Combined CTLA-4 and PD-1 Inhibitor Therapy

9:00AM-11:00AM: Abstract Number: 1580

Generalized Immune Activation in Structures Related to PMR or GCA on PET/CT Assessment Does Not Occur in Immune Checkpoint Inhibitor-Treated Patients Who Do Not Go on to Develop Rheumatic Immune-Related Adverse Events

9:00AM-11:00AM: Abstract Number: 1573

Gout as an Immune-Related Adverse Event from Immune Checkpoint Inhibitors

9:00AM-11:00AM: Abstract Number: 1570

Immune Checkpoint Inhibitor Treatment in Cancer: Immunomodulator Use and Evaluation by Rheumatology

9:00AM-11:00AM: Abstract Number: 1577

Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis Impact on Function and Patient-Reported Quality of Life Measures Varies Depending on Pattern of Arthritis

9:00AM-11:00AM: Abstract Number: 1569

Immune Related Adverse Events Related to Check Point Inhibitors Among Outpatients in an Academic Center

9:00AM-11:00AM: Abstract Number: 1568

Impact of the SARS-CoV-2 Pandemic on a Cohort of Patients with Rheumatic Complications of Immune Checkpoint Inhibitors: A Registry Survey Study

9:00AM-11:00AM: Abstract Number: 1581

Neutrophil to Lymphocyte Ratio as a Predictor of Immune-Related Adverse Events in CTLA-4 Treated Patients: A Retrospective Review

9:00AM-11:00AM: Abstract Number: 1566

Onset and Disease Course of Inflammatory Arthritis in Patients Receiving Immune Checkpoint Inhibitor Therapy at a Single Institution

9:00AM-11:00AM: Abstract Number: 1574

Over Half of Patients with Immune Checkpoint Inhibitor-related Myositis, Myasthenia Gravis and/or Myocarditis Have Autoantibodies: Results from a Systematic Literature Review

9:00AM-11:00AM: Abstract Number: 1578

Rituximab Hypersensitivity in Rheumatic and Inflammatory Diseases: Role of Skin Testing

« View all sessions from this meeting